- Oral presentation
- Open Access
Delivery of stem cells to the brain: potential for treatment of neurodegenerative disease
© Burgess et al; licensee BioMed Central Ltd. 2015
- Published: 30 June 2015
- Neural Stem Cell
- Stem Cell Therapy
- Pulse Repetition Frequency
- Superparamagnetic Iron Oxide
- Brain Tissue Damage
Stem cell therapy is a promising strategy to treat neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases. However, for stem cell therapy to be considered for clinical use, new delivery methods need to be developed. We have used focused ultrasound (FUS) as a method to induce transient opening of the blood-brain barrier (BBB) to promote the passage of therapeutic stem cells into the brain.
As a proof of principle study to demonstrate the application of this therapeutic strategy for Parkinson’s disease, we targeted the striatum using magnetic resonance imaging (MRI) for BBB opening. Definity microbubble contrast agent was injected intravenously at the onset of FUS application using a 558 kHz transducer (~0.3 MPa estimated in situ pressure, 10 ms bursts, 1 Hz pulse repetition frequency, 120 s total exposure duration).
During FUS application, neural stem cells expressing green-fluorescent protein (GFP) and labeled with superparamagnetic iron oxide (SPIO) were injected into the carotid artery. Follow up contrast enhanced MR imaging confirmed the opening of the BBB and at 24 hrs, MRI was used to detect the SPIO labeled stem cells in the region of interest. After sacrifice, GFP expressing cells were present in the targeted regions of the brain and expressed a neuronal phenotype indicative of their survival post-delivery through the BBB. Histological analysis showed some red blood cell extravasation but there was no evidence of brain tissue damage due to FUS treatment. Together, these data suggest that FUS is an efficient method for delivery of stem cells to the brain and may be the key to reducing the risks of cell transplantation helping to move stem cell therapy forward.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.